Myelomas
A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15) (224317)
- Details
ClinicalTrials.gov ID:
NCT07227311
Diagnosis Type:
NA
USOR Number:
- Address
,
P: